Novavax reported $1.38B in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adma Biologics ADMA:US $ 52.42M 17.09M
Agenus AGEN:US $ 228.38M 19.32M
AstraZeneca AZN:LN 4817M 945M
Astrazeneca AZN:US $ 4817M 945M
Biocryst Pharmaceuticals BCRX:US $ 417.48M 21.98M
Dynavax Technologies DVAX:US $ 249.09M 69.67M
Genocea Biosciences GNCA:US $ 20.14M 17.01M
Geron GERN:US $ 76.06M 44.73M
GlaxoSmithKline GSK:LN 6465M 4502M
Mannkind MNKD:US $ 35.51M 31.74M
Minerva Neurosciences NERV:US $ 49.75M 5.19M
Moderna Inc MRNA:US 2.87B 2.18B
Novartis NVS:US $ 3625M 10227M
Novavax NVAX:US $ 1375.59M 195.37M
Pain Therapeutics PTIE:US $ 197.23M 12.46M
Peregrine Pharmaceuticals PPHM:US $ 126.17M 23.79M
Sarepta Therapeutics SRPT:US $ 868.56M 365.31M
Tg Therapeutics TGTX:US $ 231.79M 46.11M